Kini G D, Robins R K, Avery T L
Department of Tumor Biology, ICN-Nucleic Acid Research Institute, Costa Mesa, California 92626.
J Med Chem. 1989 Jul;32(7):1447-9. doi: 10.1021/jm00127a008.
Methyl 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboximidate (4) and ethyl 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidate (6) were synthesized and tested for antitumor and antiviral activity. A new facile synthesis of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride (5), starting with imidate 4, was also developed. The imidates 4 and 6 differed greatly in solubility and dosing requirements. Even so, both compounds exhibited significant activity in vivo against murine leukemia L1210. Nontoxic dosing with 4 also significantly diminished Friend leukemia induced splenomegaly. In contrast, neither imidate was active in vitro.
合成了1-β-D-呋喃核糖基-1,2,4-三唑-3-甲脒亚胺酯(4)和1-β-D-呋喃核糖基-1,2,4-三唑-3-甲酰胺乙酯(6),并对其进行了抗肿瘤和抗病毒活性测试。还开发了一种从亚胺酯4开始的1-β-D-呋喃核糖基-1,2,4-三唑-3-甲脒盐酸盐(5)的新的简便合成方法。亚胺酯4和6在溶解度和给药要求上有很大差异。即便如此,这两种化合物在体内对小鼠白血病L1210均表现出显著活性。用4进行无毒给药也显著减轻了弗氏白血病诱导的脾肿大。相比之下,这两种亚胺酯在体外均无活性。